Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications
Sponsor: Sunnybrook Health Sciences Centre
Summary
'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.
Official title: A Single Centre Cohort Study to Determine if Clonal Hematopoieses of Indeterminate Potential (CHIP) is a Risk Factor for Chemotherapy-Related Complications in Lymphoma Patients >= 60 Receiving Cytotoxic Chemotherapy
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
OBSERVATIONAL
Enrollment
188
Start Date
2019-08-08
Completion Date
2026-09
Last Updated
2025-07-08
Healthy Volunteers
Not specified
Conditions
Interventions
Blood test for determination of CHIP
Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
Locations (1)
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada